How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)
With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).
China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)
Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3).
China’s NRDL 2022 Update: A Snapshot and Overall Trends (Part 1 of 3)
In China’s rapidly growing pharma market, the NRDL is the main path to market access. And it’s changed. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what the updates mean for multinationals in this free brief (part 1 of 3).
